Our Equity Capital Markets and Life Sciences team has successfully assisted Prescient Therapeutics Limited in its $11.3 million capital raising, via an $8.8 million Share Purchase Plan (SPP), and a $2.5 million follow up placement. 

Prescient Therapeutics specialises in clinical stage oncology with a focus on developing novel, personalised therapies for a range of cancers to improve outcomes for patients by creating new tools for clinicians to combat cancer.

The funds raised will provide progression for Prescient Therapeutics’ ongoing clinical development of its targeted therapies PTX-100 and PTX-200, and development of its innovative cell therapies towards first-in-human clinical studies.

Lead partner, Ben Wood comments “we have advised Prescient Therapeutics since 2015 across its capital raising and corporate needs, and we’re proud to have again supported the team on this capital raise. Congratulations to the team at Prescient Therapeutics, and to all involved”.